Dendrimer Nanotherapy for Severe COVID-19 Attenuates Inflammation and Neurological Injury Markers and Improves Outcomes in a Phase IIa Clinical Trial

In this multicenter, randomized, double-blind, placebo-controlled, adaptive Phase IIa trial, investigators evaluated safety and preliminary efficacy of OP-101, a hydroxyl-polyamidoamine dendrimer–N-acetylcysteine conjugate that specifically targeted activated macrophages, in patients with severe COVID-19.